Tag Archives: Jotin Marango
Savara Inc (SVRA) Gets a Hold Rating from Roth Capital
In a report released today, Jotin Marango from Roth Capital maintained a Hold rating on Savara Inc (SVRA – Research Report), with a price target of $10. The company’s shares opened today at $11.26. Marango commented: “We assign a 15%
Roth Capital Maintains Their Buy Rating on Anavex Life Sciences (AVXL)
In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report), with a price target of $10. The company’s shares opened today at $3. Marango commented: “We are encouraged
Roth Capital Believes Resverlogix (TSX: RVX) Still Has Room to Grow
Resverlogix (RVX – Research Report), the Healthcare company, has received a rating update from a Wall Street analyst today. Roth Capital’s analyst Jotin Marango reiterates their Buy rating on the shares, with a C$10 price target. Marango observed: “We remain
Analysts Offer Insights on Healthcare Companies: Verastem (NASDAQ: VSTM) and Sientra (NASDAQ: SIEN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verastem (VSTM – Research Report) and Sientra (SIEN – Research Report) with bullish sentiments. Verastem (VSTM) Roth Capital analyst Jotin Marango maintained
Roth Capital Keeps a Buy Rating on Arqule (ARQL)
Roth Capital analyst Jotin Marango maintained a Buy rating on Arqule (ARQL – Research Report) today and set a price target of $8. The company’s shares opened today at $4.51. Marango commented: “We are increasingly bullish on this orphan program,
Roth Capital Sticks to Its Buy Rating for Aimmune Therapeutics (AIMT)
In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Aimmune Therapeutics (AIMT – Research Report), with a price target of $80. The company’s shares closed yesterday at $24.09. Marango observed: “We expect to hear
